At Blue Genes, we’re optimizing patient prescribing with cutting-edge genetic testing—because knowledge is the key to better health.
At Blue Genes, we’re redefining healthcare with cutting-edge genetic testing—because knowledge is the key to better health.
The Blue Genes marketplace is where you order TRU-1, Lumyn and PULS, track shipping, read your results, and talk to Genie — one account from checkout to report.
At Blue Genes, we’re redefining healthcare with cutting-edge genetic testing—because knowledge is the key to better health.
At Blue Genes, we’re redefining healthcare with cutting-edge genetic testing—because knowledge is the key to better health.
Nick Glimcher is the CEO of PrimeBody, Genetic Technological Innovations, LLC (GTI Labs), and Blue Genes Labs, LLC—three companies driving innovation across personalized healthcare, diagnostics, and wellness.
After graduating from Arizona State University in 2001 with a bachelor’s degree in Real Estate and Finance, Nick founded GVSW, a real estate development firm that built and acquired over $300 million in commercial shopping centers throughout Arizona, California, and Utah between 2001 and 2009.
In 2004, he launched NR Glimcher, executing more than $100 million in sale-leaseback transactions across numerous states including Arizona, California, Kansas, Alabama, North Carolina, South Carolina, Florida, and Georgia.
Nick’s entrepreneurial journey expanded into fintech with the founding of BlueSquare Resolutions in 2009, which was later ranked #19 on Inc. magazine’s list of the 500 fastest-growing companies in America. BlueSquare processed over $10 billion in credit card transactions before its acquisition by a Goldman Sachs–backed firm in 2015.
In 2014, Nick acquired PrimeBody, now a nationally recognized hormone replacement therapy provider operating across the United States. Two years later, he purchased Genetic Technological Innovations (GTI Labs), which currently operates in 40 states and delivers cutting-edge diagnostics and personalized health solutions.
In 2021, Nick founded Blue Genes Labs, LLC with a mission to transform how prescriptions are delivered through the power of precision medicine. At Blue Genes, the vision is bold and clear: build the future of precision medicine—one that works smarter for everyone. The platform empowers providers, health plans, and patients with tools to reduce adverse drug reactions, eliminate unnecessary prescribing, and lower the overall cost of care. Through a unified technology system that streamlines clinical workflows and delivers personalized insights at the point of care, Blue Genes is redefining healthcare—making it safer, more efficient, and truly collaborative.
Dr. Massey is a neuropharmacologist, pharmacogeneticist, life sciences professional, senior executive, inventor and entrepreneur. He is currently the Chief Medical Officer for Blue Genes and GTI Laboratories. Dr. Massey received his Ph.D. in Pharmacology at the University of Arkansas for Medical Sciences. He conducted his post-doctoral research at The University of Chicago’s Pritzker School of Medicine. Subsequently, Dr. Massey joined the AstraMerck Group of Merck and Company culminating his career as head of CNS Regulatory Affairs. After Astra Merck, Dr. Massey held senior management positions at Quintiles and AstraZeneca. In 2011, Dr. Massey became the Jack Martin, MD Professor of Psychopharmacology at Vanderbilt University, where he conducted research into the genetics, biological basis and pharmacological treatment of schizophrenia and serious mental illness. Following his tenure at Vanderbilt, Dr. Massey has been involved in leading PGx and personalized medicine companies. Dr. Massey currently holds adjunct faculty appointments at the University of Arkansas for Medical Sciences. He continues to conduct and publish globally recognized research in the areas of neuropharmacology, mental illness and pharmacogenetics.
Chris brings over two decades of executive leadership across healthcare technology, digital production, and enterprise innovation. With a unique blend of financial strategy and technical oversight, Chris plays a pivotal role in guiding the company’s long-term growth, overseeing compliance initiatives, and scaling Blue Genes' proprietary pharmacogenetic platforms for broader healthcare integration.
Before joining Blue Genes, Chris founded and led several technology ventures, including Titanium 6, where he has developed custom apps and branding platforms for high-profile clients. His extensive background spans CTO roles at healthcare and advertising firms, where he designed operational infrastructure, drove product innovation, and led teams through complex digital transformations. He is also a Microsoft Certified Solutions Developer and Trainer, with credentials in networking, digital systems, and internet technologies.
Edith Pando is an accomplished financial and operational executive with over 15 years of experience guiding organizational strategy, financial planning, and operational excellence. As the Chief Financial Officer and Chief Operating Officer at Genetic Technological Innovations, she oversees the company’s financial health while ensuring day-to-day operations align with long-term business goals.
With a deep background in financial analysis, tax strategy, and regulatory compliance, Edith has successfully led enterprise-wide budgeting, capital planning, and process optimization efforts. Her dual leadership role reflects her exceptional ability to bridge fiscal strategy with efficient execution—driving profitability, accountability, and sustainable growth.
Edith is an IRS Enrolled Agent and holds a B.S. in Accountancy from Arizona State University. Prior to her executive leadership at GTI, she served as Senior Partner at A&A Accounting and Tax Services and as Controller at Pacific Gold Mortgage, where she developed a reputation for building strong teams and delivering results through integrity and innovation.
Based in Scottsdale, Arizona, Edith is a dedicated leader who thrives in collaborative environments and brings a proactive, solutions-focused approach to every challenge.
Gayle has over a decade of experience in the diagnostic and genetic laboratory sector. She has played a key role in enhancing both the pre-analytic and post-analytic operations at Blue Genes, focusing on operational efficiency and strategy formulation. As the leader of our Customer Success Team, she ensures that both our organizations and clients fully understand how Blue Genes operates and have an exceptional experience. She possesses expertise in managing cross-functional teams, spearheading strategic projects, cultivating strong connections with clients, and achieving measurable outcomes. Gayle earned her B.S. degree in Biology Pre-Medicine from Grand Canyon University.
Rebecca Ginsburg serves as the Chief Scientific Officer at GTI Laboratories, where she oversees multidisciplinary laboratory operations spanning five departments. Since joining the company in 2017, Rebecca has been instrumental in shaping GTI’s scientific direction and driving its evolution from a specialized lab to a robust, compliance-driven organization recognized for excellence in innovation and operational rigor.
Bringing over 12 years of experience in clinical laboratory science, Rebecca began her career with a strong technical grounding in toxicology and LC-MS instrumentation. Her expertise in complex analytical platforms laid the foundation for her transition into regulatory leadership, where she became a pivotal force in aligning scientific workflows with CAP, CLIA, and diverse state regulatory frameworks.
At GTI, Rebecca has led major initiatives to expand testing capabilities, streamline departmental workflows, and standardize validation protocols. Her strategic vision and hands-on leadership have guided the lab through critical inspections, complex compliance environments, and cross-functional growth. Known for her ability to bridge technical depth with operational excellence, she fosters collaboration across teams, enabling sustainable and scalable scientific progress.
Rebecca holds a Bachelor’s degree in Biology and is deeply committed to advancing the field of laboratory medicine through mentorship, systems thinking, and an unwavering dedication to quality.